Home | FCA & regulatory news | British English edition
Trade Hub UK

Independent coverage of UK markets, FCA policy and institutional trading
AD Bank of England Statistics AD Investing.com Markets AD LSEG Data AD CME Group Education
Venues & MTFs

Lilly's Omvoh Meets Primary Endpoint In Phase 3 Pediatric Ulcerative Colitis Study

Trade Hub UK regulation desk (2026-10-19): Lilly's Omvoh Meets Primary Endpoint In Phase 3 Pediatric Ulcerative Colitis Study (RTTNews) - One in two pediatric ulcerative colitis patients who responded… Primary source: original at Nasdaq Market Structure (nasdaq.com).

By Nasdaq Market Structure

Lilly's Omvoh Meets Primary Endpoint In Phase 3 Pediatric Ulcerative Colitis Study

(RTTNews) - One in two pediatric ulcerative colitis patients who responded to initial treatment with Omvoh remained in clinical remission after one year in a Phase 3 study, as Eli Lilly and Company (LLY) reported positive results from the SHINE-2 trial evaluating the therapy in c

Read at source

Read also
  1. OSE Immunotherapeutics' Tedopi Combination Meets Primary Endpoint In NSCLC Trial
  2. Veradermics To Review Phase 3 Study 304 Results For VDPHL01 In Male Pattern Hair Loss; Stock Up
  3. Disc Medicine Set To Report Phase 3 Bitopertin Results In Rare Blood Disorder; Stock Up
  4. Propanc Reports Preclinical Data For PRP In Chemoresistance; Phase 1 Set For Q1 '27
  5. Warren Buffett Warned About Stock Valuations. So Why Is Berkshire Still Buying Stocks?

Source: Nasdaq Market Structure